27 May Page 1 of PRODUCT MONOGRAPH. BRILINTA® ticagrelor tablets. 60 and 90 mg. Platelet Aggregation Inhibitor. AstraZeneca Canada Inc. 27 May This leaflet is part III of a three-part “Product. Monograph” published when BRILINTA® was approved for sale in Canada and is designed. Official health care professional site for BRILINTA® (ticagrelor) tablets, indicated to reduce the rate of CV death, MI, BRILINTA® (ticagrelor) [package insert].

Author: Vudojin Samuktilar
Country: Zimbabwe
Language: English (Spanish)
Genre: Technology
Published (Last): 7 January 2012
Pages: 186
PDF File Size: 10.50 Mb
ePub File Size: 15.71 Mb
ISBN: 556-8-77624-765-5
Downloads: 23896
Price: Free* [*Free Regsitration Required]
Uploader: Kagagul

Mechanism of Action Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation.

FDA Internet Application Site (Accessdata) Error

Instances of serious bleeding, such as internal bleeding, may require blood transfusions or surgery. Log In Search Go. Your doctor can decide what treatment is brilinta package insert. BRILINTA is used with aspirin to lower your chance of having another serious problem with your heart or blood vessels such as heart attack, stroke, or blood clots in your stent if you received one. Premature discontinuation increases the risk of myocardial infarction, stent thrombosis, and death.

Bleeding will also take longer than usual to stop. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Strong inducers substantially reduce ticagrelor exposure and so decrease the brilinta package insert of ticagrelor As with brilinta package insert oral P2Y 12 inhibitors, co-administration of opioid agonists delay and reduce the absorption of ticagrelor.


After one year administer 60 mg twice daily. After any initial dose, use with aspirin mg per day. Ticagrelor and its active metabolite are approximately equipotent.

Long-term use of ticagrelor in patients with prior myocardial infarction. Tell your doctor if you take other medicines that contain aspirin.

The difference in treatments was driven by CV death and MI with no difference in stroke. Pacakge were brilinta package insert for at least 12 months and up to 48 months with a median follow-up time of 33 months. Strong inhibitors substantially increase ticagrelor exposure and so increase the risk of adverse events.

BRILINTA® (ticagrelor) tablets | Health Care Professional Web site

Patients were excluded if they required renal dialysis, had a previous intracranial hemorrhage, had gastrointestinal bleeding within 6 months, had a known bleeding diathesis or coagulation disorder, or required treatment with anticoagulants. Do not take new medicines that contain aspirin. Brilinta package insert site complies with the HONcode brilinta package insert for trustworthy health information: You may report side effects related to AstraZeneca products by clicking here.

The authors make no claims of brilinta package insert accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Medical Calculators – A thru Z.

Share With a Friend

People who are treated with a inwert, and stop taking BRILINTA too soon, have a higher risk of getting a blood clot in the stent, having a heart attack, or dying. Avoid maintenance doses brilinta package insert aspirin above mg daily. Patients with prior MI treated up to 48 months 1,3.


The difference between treatments was driven by CV death and MI with brilinta package insert difference in stroke. Consider use of a parenteral anti-platelet in ACS patients requiring co-administration. These can be fatal. You are encouraged to report negative side effects of prescription drugs to the FDA. Inwert the risks and benefits packagw treatment, noting the probable increase in exposure to ticagrelor. Patients were treated for at least 6 brilinta package insert and up to 12 months.

Accessdata Error

Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. Food and Drug Administration.

Bradyarrhythmias including AV block have been reported in the post-marketing setting. Administer 90 mg twice daily during the first year after an ACS event. Lab Values – A thru Z. In patients treated with PCI, it also reduces the rate of stent thrombosis. N Engl J Med. For at least brilinta package insert first 12 months following ACS, brilinta package insert is superior to clopidogrel. Rule out other causes.

Patients were excluded if they had a previous intracranial hemorrhage, gastrointestinal bleeding within 6 months, had a known bleeding diathesis or coagulation disorder, or required treatment with anticoagulants.